Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
856 questions in 87 reviews · Cystic Fibrosis and Genetic Disorders
current versionsNo studies 856 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Single foetal haemoglobin inducer at any dose or duration vs usual care or placebo Frequency of transfusion (transfused volume/year) · people with non‐transfusion‐dependent β‐thalassaemia Foetal haemoglobin inducers for reducing blood transfusion in non‐transfusion‐dependent beta‐thalassaemias (2023) · Cochrane | no estimate extracted | NR | No studies |
Single foetal haemoglobin inducer at any dose or duration vs another foetal haemoglobin inducer QoL · people with non‐transfusion‐dependent β‐thalassaemia Foetal haemoglobin inducers for reducing blood transfusion in non‐transfusion‐dependent beta‐thalassaemias (2023) · Cochrane | no estimate extracted | NR | No studies |
One dose or dose regimen of a foetal haemoglobin inducer vs another dose or dose regimen of the same foetal haemoglobin inducer Frequency of transfusion (transfused volume/ year) · people with non‐transfusion‐dependent β‐thalassaemia Foetal haemoglobin inducers for reducing blood transfusion in non‐transfusion‐dependent beta‐thalassaemias (2023) · Cochrane | no estimate extracted | NR | No studies |
One dose or dose regimen of a foetal haemoglobin inducer vs another dose or dose regimen of the same foetal haemoglobin inducer Transfusion‐free interval (days) · people with non‐transfusion‐dependent β‐thalassaemia Foetal haemoglobin inducers for reducing blood transfusion in non‐transfusion‐dependent beta‐thalassaemias (2023) · Cochrane | no estimate extracted | NR | No studies |
One dose or dose regimen of a foetal haemoglobin inducer vs another dose or dose regimen of the same foetal haemoglobin inducer QoL · people with non‐transfusion‐dependent β‐thalassaemia Foetal haemoglobin inducers for reducing blood transfusion in non‐transfusion‐dependent beta‐thalassaemias (2023) · Cochrane | no estimate extracted | NR | No studies |
Single foetal haemoglobin inducer at any dose or duration vs usual care or placebo Transfusion‐free interval (days) · people with non‐transfusion‐dependent β‐thalassaemia Foetal haemoglobin inducers for reducing blood transfusion in non‐transfusion‐dependent beta‐thalassaemias (2023) · Cochrane | no estimate extracted | NR | No studies |
Two or more foetal haemoglobin inducers at any dose or duration vs a usual management protocol, placebo or a single foetal haemoglobin inducer Frequency of transfusion (transfused volume/year) · people with non‐transfusion‐dependent β‐thalassaemia Foetal haemoglobin inducers for reducing blood transfusion in non‐transfusion‐dependent beta‐thalassaemias (2023) · Cochrane | no estimate extracted | NR | No studies |
Two or more foetal haemoglobin inducers at any dose or duration vs a usual management protocol, placebo or a single foetal haemoglobin inducer Transfusion‐free interval (days) · people with non‐transfusion‐dependent β‐thalassaemia Foetal haemoglobin inducers for reducing blood transfusion in non‐transfusion‐dependent beta‐thalassaemias (2023) · Cochrane | no estimate extracted | NR | No studies |
Two or more foetal haemoglobin inducers at any dose or duration vs a usual management protocol, placebo or a single foetal haemoglobin inducer HbF levels (%) · people with non‐transfusion‐dependent β‐thalassaemia Foetal haemoglobin inducers for reducing blood transfusion in non‐transfusion‐dependent beta‐thalassaemias (2023) · Cochrane | no estimate extracted | NR | No studies |
Two or more foetal haemoglobin inducers at any dose or duration vs a usual management protocol, placebo or a single foetal haemoglobin inducer QoL · people with non‐transfusion‐dependent β‐thalassaemia Foetal haemoglobin inducers for reducing blood transfusion in non‐transfusion‐dependent beta‐thalassaemias (2023) · Cochrane | no estimate extracted | NR | No studies |
Single foetal haemoglobin inducer at any dose or duration vs usual care or placebo QoL · people with non‐transfusion‐dependent β‐thalassaemia Foetal haemoglobin inducers for reducing blood transfusion in non‐transfusion‐dependent beta‐thalassaemias (2023) · Cochrane | no estimate extracted | NR | No studies |
Single foetal haemoglobin inducer at any dose or duration vs another foetal haemoglobin inducer Frequency of transfusion (transfused volume/year) · people with non‐transfusion‐dependent β‐thalassaemia Foetal haemoglobin inducers for reducing blood transfusion in non‐transfusion‐dependent beta‐thalassaemias (2023) · Cochrane | no estimate extracted | NR | No studies |
Single foetal haemoglobin inducer at any dose or duration vs another foetal haemoglobin inducer Transfusion‐free interval (days) · people with non‐transfusion‐dependent β‐thalassaemia Foetal haemoglobin inducers for reducing blood transfusion in non‐transfusion‐dependent beta‐thalassaemias (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings for nasal irrigation with topical steroids plus sinus surgery vs nasal irrigation with topical steroids alone Mortality · children and adults diagnosed with cystic fibrosis and chronic rhinosinusitis with nasal polyposis Surgery for nasal polyposis in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Exercise prescription plus the use of a wearable fitness tracker vs exercise prescription alone Adherence to exercise training (long term) · adults with CF Digital technology for delivering and monitoring exercise programs for people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Wearable fitness tracker plus text message for personalized feedback and goal setting vs wearable fitness tracker alone Time to subsequent pulmonary exacerbation (medium term) · adults with CF Digital technology for delivering and monitoring exercise programs for people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Wearable fitness tracker plus text message for personalized feedback and goal setting vs wearable fitness tracker alone Usability of digital health technology (medium term) · adults with CF Digital technology for delivering and monitoring exercise programs for people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Wearable fitness tracker plus text message for personalized feedback and goal setting vs wearable fitness tracker alone QoL (long term) · adults with CF Digital technology for delivering and monitoring exercise programs for people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Wearable fitness tracker plus text message for personalized feedback and goal setting vs wearable fitness tracker alone Exercise capacity (long term) · adults with CF Digital technology for delivering and monitoring exercise programs for people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Web‐based application to record, monitor and set goals on physical activity plus usual care vs usual care alone Adherence to exercise training (long term) · adolescents and adults with CF Digital technology for delivering and monitoring exercise programs for people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Web‐based application to record, monitor and set goals on physical activity plus usual care vs usual care alone Self‐management behavior (long term) · adolescents and adults with CF Digital technology for delivering and monitoring exercise programs for people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Web‐based application to record, monitor and set goals on physical activity plus usual care vs usual care alone Usability of digital health technology (medium term) · adolescents and adults with CF Digital technology for delivering and monitoring exercise programs for people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Web‐based application to record, monitor and set goals on physical activity plus usual care vs usual care alone QoL (long term) · adolescents and adults with CF Digital technology for delivering and monitoring exercise programs for people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Exercise prescription plus the use of a wearable fitness tracker vs exercise prescription alone Self‐management behavior (long term) · adults with CF Digital technology for delivering and monitoring exercise programs for people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Web‐based application to record, monitor and set goals on physical activity plus usual care vs usual care alone Exercise capacity (long term) · adolescents and adults with CF Digital technology for delivering and monitoring exercise programs for people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Web‐based vs face‐to‐face exercise delivery Adherence to exercise training (long term) · children and adults with CF Digital technology for delivering and monitoring exercise programs for people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Web‐based vs face‐to‐face exercise delivery Self‐management behavior (long term) · children and adults with CF Digital technology for delivering and monitoring exercise programs for people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Web‐based vs face‐to‐face exercise delivery Time to subsequent pulmonary exacerbation (medium term) · children and adults with CF Digital technology for delivering and monitoring exercise programs for people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Web‐based vs face‐to‐face exercise delivery Usability of digital health technology (medium term) · children and adults with CF Digital technology for delivering and monitoring exercise programs for people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Web‐based vs face‐to‐face exercise delivery QoL: CFQ‐R scores (long term) · children and adults with CF Digital technology for delivering and monitoring exercise programs for people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Web‐based vs face‐to‐face exercise delivery Exercise capacity · children and adults with CF Digital technology for delivering and monitoring exercise programs for people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Exercise prescription plus the use of a wearable fitness tracker vs exercise prescription alone Time to subsequent pulmonary exacerbation (medium term) · adults with CF Digital technology for delivering and monitoring exercise programs for people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Exercise prescription plus the use of a wearable fitness tracker vs exercise prescription alone Usability of digital health technology (medium term) · adults with CF Digital technology for delivering and monitoring exercise programs for people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Exercise prescription plus the use of a wearable fitness tracker vs exercise prescription alone QoL: CFQ‐R scores (long term) · adults with CF Digital technology for delivering and monitoring exercise programs for people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Exercise prescription plus the use of a wearable fitness tracker vs exercise prescription alone Exercise capacity – submaximal GXT (long term) · adults with CF Digital technology for delivering and monitoring exercise programs for people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Wearable fitness tracker plus text message for personalized feedback and goal setting vs wearable fitness tracker alone Adherence to exercise training (long term) · adults with CF Digital technology for delivering and monitoring exercise programs for people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Wearable fitness tracker plus text message for personalized feedback and goal setting vs wearable fitness tracker alone Self‐management behavior (long term) · adults with CF Digital technology for delivering and monitoring exercise programs for people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: inhaled TOBI® (IV preparation) vs tobramycin Pulmonary exacerbations · adults and children with CF and P aeruginosa Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: inhaled TOBI® (IV preparation) vs tobramycin Quality of life · adults and children with CF and P aeruginosa Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: inhaled TOBI® (IV preparation) vs tobramycin Survival · adults and children with CF and P aeruginosa Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: inhaled TOBI® (IV preparation) vs tobramycin Antibiotic resistance · adults and children with CF and P aeruginosa Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: inhaled TOBI® (IV preparation) vs tobramycin Adverse events · adults and children with CF and P aeruginosa Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: tobramycin for inhalation powder vs tobramycin FVC · children and adults with CF and P aeruginosa Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: tobramycin for inhalation powder vs tobramycin Quality of life · children and adults with CF and P aeruginosa Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: aztreonam lysine for inhalation vs tobramycin FVC · children and adults with CF and P aeruginosa Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: amikacin liposome inhalation suspension (ALIS) vs tobramycin FVC · children and adults with CF and P aeruginosa Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: amikacin liposome inhalation suspension (ALIS) vs tobramycin Survival · children and adults with CF and P aeruginosa Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: levofloxacin for inhalation solution vs tobramycin Survival · adults and children aged over 12 with CF and P aeruginosa Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: continuous cycles alternating aztreonam lysine for inhalation with tobramycin for inhalation solution vs continuous cycles alternating placebo with tobramycin FVC · children and adults with CF and P aeruginosa Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: continuous cycles alternating aztreonam lysine for inhalation with tobramycin for inhalation solution vs continuous cycles alternating placebo with tobramycin Survival · children and adults with CF and P aeruginosa Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |